Y-mabs announces preclinical gd2-sada data to be presented at 2024 snmmi annual meeting

New york, june 07, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical gd2-sada data will be presented at the society of nuclear medicine & molecular imaging (snmmi) 2024 annual meeting taking place june 8 – 11, 2024, in toronto, canada.
YMAB Ratings Summary
YMAB Quant Ranking